Skip to main content
Equibles
IKT logo

IKT · Inhibikase Therapeutics, Inc.

Track IKT — free

Use IKT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IKT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.41 +0.00 (+0.00%) At close · Aug 14
Market Cap
$336.28M
Shares
139.54M

Inhibikase Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Inhibikase Therapeutics, Inc. (IKT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼99.5% $6,552 −$4.64M '22 Q2 22-06-30 ▼97.8% $7,291 −$4.49M '22 Q3 22-11-17 ▲3169.9% $63,566 −$4.28M '22 Q4 22-12-31 ▲40.2% $64,521 −$4.48M '23 Q1 23-03-31 ▲1676.7% $116,410 −$5.78M '23 Q2 23-06-30 ▲991.3% $79,569 −$4.60M '23 Q3 23-09-30 ▼100% $1 −$4.18M '23 Q4 23-12-31 ▼100% $ −$4.65M '24 Q1 24-03-31 ▼100% $ −$4.96M '24 Q2 24-06-30 ▼100% $ −$12.13M '24 Q4 25-03-27 · $ −$13.68M '25 Q1 25-05-14 · $ −$9.92M '25 Q2 25-08-14 · $ −$11.93M '25 Q3 25-11-14 · $ −$16.38M '26 Q1 26-05-12 LATEST · $ −$19.59M '26 Q2 26-08-11
Earnings call
FY26 · Q2
2026-08-11
Inhibikase Therapeutics, Inc. Q2 FY2026 Earnings Call
Revenue
$
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Inhibikase Therapeutics, Inc. Q1 FY2026 Earnings Call
Revenue
$
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Inhibikase Therapeutics, Inc. Q4 FY2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Inhibikase Therapeutics, Inc. Q3 FY2025 Earnings Call
Revenue
$
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Inhibikase Therapeutics, Inc. Q2 FY2025 Earnings Call
Revenue
$
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Inhibikase Therapeutics, Inc. Q1 FY2025 Earnings Call
Revenue
$
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Inhibikase Therapeutics, Inc. Q4 FY2024 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-06-30
Inhibikase Therapeutics, Inc. Q2 FY2024 Earnings Call
Positive tone IkT-001Pro in pulmonary arterial hypertension Cash position and capital needs Biomarker and diagnostic tools
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Inhibikase Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone Pulmonary Arterial Hypertension (PAH) Opportunity Alpha-Synuclein Biomarker and Antibody Development Capital Needs and Financing Constraints
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Inhibikase Therapeutics, Inc. Q4 FY2023 Earnings Call
Revenue
$1*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Inhibikase Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$79,569
▲ 991.3% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Inhibikase Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$116,410
▲ 1676.7% YoY
Diluted EPS
$-1.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Inhibikase Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$64,521
▲ 40.2% YoY
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Inhibikase Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$63,566*
▲ 3169.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-17
Inhibikase Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$7,291
▼ 97.8% YoY
Diluted EPS
$-1.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Inhibikase Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$6,552
▼ 99.5% YoY
Diluted EPS
$-1.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Inhibikase Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$46,031
▼ 96.7% YoY
Diluted EPS
$-1.08
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Inhibikase Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$1,944*
▼ 98.9% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q1
2021-04-01
Inhibikase Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$1.41M
▲ 419.7% YoY
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–19 of 19 earnings calls
Key facts CIK 1750149 CUSIP 45719W205 13F (30d) 106 filings 104 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)